DNase1: a new personalized therapy for cancer?

References

• Wolchok JD, Neyns B, Linette G et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, Phase 2, dose-ranging study. Lancet Oncol.11(2), 155–164 (2010).
   PubMed Web of Science ®Google Scholar
• Garber K. Industry makes strides in melanoma. Nat. Biotechnol.28(8), 763–764 (2010).
   PubMedGoogle Scholar
• Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med.363(9), 809–819 (2010).
   PubMed Web of Science ®Google Scholar
• Solit D, Sawyers CL. Drug discovery: how melanomas bypass new therapy. Nature468(7326), 902–903 (2010).
   PubMed Web of Science ®Google Scholar
• Melino G, Knight RA, Nicotera P. How many ways to die? How many different models of cell death? Cell Death Differ.12(Suppl. 2), 1457–1462 (2005).
   PubMed Web of Science ®Google Scholar
• Bargou RC, Wagener C, Bommert K et al. Overexpression of the death-promoting gene bax-α which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J. Clin. Invest.97(11), 2651–2659 (1996).
   PubMed Web of Science ®Google Scholar
• Smalley KS. Understanding melanoma signaling networks as the basis for molecular targeted therapy. J. Invest. Dermatol.130(1), 28–37 (2010).
   PubMed Web of Science ®Google Scholar
• Rosner K, Kasprzak MF, Horenstein AC et al. Engineering a waste management enzyme to overcome cancer resistance to apoptosis: adding DNase1 to the anti-cancer toolbox. Cancer Gene Ther.18(5), 346–357 (2011).
   PubMedGoogle Scholar
• Baranovskii AG, Buneva VN, Nevinsky GA. Human deoxyribonucleases. Biochemistry (Mosc.)69(6), 587–601 (2004).
   PubMedGoogle Scholar
• Napirei M, Karsunky H, Zevnik B, Stephan H, Mannherz HG, Moroy T. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat. Genet.25(2), 177–181 (2000).
   PubMed Web of Science ®Google Scholar
• Yasutomo K, Horiuchi T, Kagami S et al. Mutation of DNASE1 in people with systemic lupus erythematosus. Nat. Genet.28(4), 313–314 (2001).
   PubMed Web of Science ®Google Scholar
• Shiokawa D, Tanuma S. Characterization of human DNase I family endonucleases and activation of DNase γ during apoptosis. Biochemistry40(1), 143–152 (2001).
   PubMed Web of Science ®Google Scholar
• Samejima K, Earnshaw WC. Trashing the genome: the role of nucleases during apoptosis. Nat. Rev. Mol. Cell Biol.6(9), 677–688 (2005).
   PubMed Web of Science ®Google Scholar
• Napirei M, Wulf S, Mannherz HG. Chromatin breakdown during necrosis by serum Dnase1 and the plasminogen system. Arthritis Rheum.50(6), 1873–1883 (2004).
   PubMed Web of Science ®Google Scholar
• Oliveri M, Daga A, Cantoni C, Lunardi C, Millo R, Puccetti A. DNase I mediates internucleosomal DNA degradation in human cells undergoing drug-induced apoptosis. Eur. J. Immunol.31(3), 743–751 (2001).
   PubMed Web of Science ®Google Scholar
• Bullani RR, Wehrli P, Viard-Leveugle I et al. Frequent downregulation of Fas (CD95) expression and function in melanoma. Melanoma Res.12(3), 263–270 (2002).
   PubMed Web of Science ®Google Scholar
• Hopkins-Donaldson S, Bodmer JL, Bourloud KB, Brognara CB, Tschopp J, Gross N. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res.60(16), 4315–4319 (2000).
   PubMed Web of Science ®Google Scholar
• Tamm I, Wang Y, Sausville E et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res.58(23), 5315–5320 (1998).
   PubMed Web of Science ®Google Scholar
• Kishi K, Yasuda T, Takeshita H. DNase I: structure, function, and use in medicine and forensic science. Leg. Med. (Tokyo).3(2), 69–83 (2001).
   PubMedGoogle Scholar
• Eulitz D, Mannherz HG. Inhibition of deoxyribonuclease I by actin is to protect cells from premature cell death. Apoptosis12(8), 1511–1521 (2007).
   PubMedGoogle Scholar
• Mesa C, Fernández LE. Challenges facing adjuvants for cancer immunotherapy. Immunol. Cell Biol.82(6), 644–650 (2004).
   PubMed Web of Science ®Google Scholar
• Xu LF, Xu DH, Ge K, Zheng ZC, Sun LY, Liu XY. The use of suicide gene systems in vascular cells in vitro. Cell Res.8(1), 73–78 (1998).
   PubMedGoogle Scholar
• Al-Hendy A, Auersperg N. Applying the herpes simplex virus thymidine kinase/ganciclovir approach to ovarian cancer: an effective in vitro drug-sensitization system. Gynecol. Obstet. Invest.43(4), 268–275 (1997).
   PubMedGoogle Scholar
• Yang J, Liu TJ, Lu Y. Effects of bicistronic lentiviral vector-mediated herpes simplex virus thymidine kinase/ganciclovir system on human lens epithelial cells. Curr. Eye Res.32(1), 33–42 (2007).
   PubMed Web of Science ®Google Scholar
• Qian C, Idoate M, Bilbao R et al. Gene transfer and therapy with adenoviral vector in rats with diethylnitrosamine-induced hepatocellular carcinoma. Hum. Gene Ther.8(3), 349–358 (1997).
   PubMed Web of Science ®Google Scholar
• Altaner C. Prodrug cancer gene therapy. Cancer Lett.270(2), 191–201 (2008).
   PubMed Web of Science ®Google Scholar
• Vile RG, Castleden S, Marshall J, Camplejohn R, Upton C, Chong H. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int. J. Cancer71(2), 267–274 (1997).
   PubMed Web of Science ®Google Scholar
• Pan CQ, Dodge TH, Baker DL, Prince WS, Sinicropi DV, Lazarus RA. Improved potency of hyperactive and actin-resistant human DNase I variants for treatment of cystic fibrosis and systemic lupus erythematosus. J. Biol. Chem.273(29), 18374–18381 (1998).
   PubMed Web of Science ®Google Scholar
• Kidera Y, Tsubaki M, Yamazoe Y et al. Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho-associated coiled-coil-containing protein kinase pathway. J. Exp. Clin. Cancer Res.29, 127 (2010).
   PubMedGoogle Scholar
• Dalerba P, Ricci A, Russo V et al. High homogeneity of MAGE, BAGE, GAGE, tyrosinase and Melan-A/MART-1 gene expression in clusters of multiple simultaneous metastases of human melanoma: implications for protocol design of therapeutic antigen-specific vaccination strategies. Int. J. Cancer77(2), 200–204 (1998).
   PubMed Web of Science ®Google Scholar
• Poulsen TT, Pedersen N, Poulsen HS. Replacement and suicide gene therapy for targeted treatment of lung cancer. Clin. Lung Cancer6(4), 227–236 (2005).
   PubMedGoogle Scholar
• Saukkonen K, Hemminki A. Tissue-specific promoters for cancer gene therapy. Expert Opin. Biol. Ther.4(5), 683–696 (2004).
   PubMed Web of Science ®Google Scholar